ArticleScientific reports2015
Single cell resolution in vivo imaging of DNA damage following PARP inhibition.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 66 citations in OpenAlex.
- In vivo DNA damage protection during cell migration across confining embryonic tissue environments.Nature cell biology · 2026Article
- Emerging In Vivo Imaging Modalities for Improved Glioblastoma Surgery and Monitoring.Biomedicines · 2026Review
- Temozolomide increases the generation of cell heterogeneity in ERK activity in glioma cells.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Genetically Encoded Cell Fate Reporter System for Multiplex Single-Cell Detection of DNA and Mitochondrial Damage.ACS omega · 2025Article
- Mitochondria-derived nuclear ATP surge protects against confinement-induced proliferation defects.Nature communications · 2025Article
- Cell confluency affects p53 dynamics in response to DNA damage.Molecular biology of the cell · 2025Article
- γ-tubulin mediates DNA double-strand break repair.Journal of cell science · 2025Article
- Ferrocene thiazolidine-2,4-dione derivatives cause DNA damage and interfere with DNA repair in triple-negative breast cancer cells.PloS one · 2025Article
- Distinct mobility patterns of BRCA2 molecules at DNA damage sites.Nucleic acids research · 2024Article
- PARP trapping is governed by the PARP inhibitor dissociation rate constant.Cell chemical biology · 2024Article
- Temozolomide resistance mechanisms: unveiling the role of translesion DNA polymerase kappa in glioblastoma spheroids in vitro.Bioscience reports · 2024Article
- Transmembrane nuclease NUMEN/ENDOD1 regulates DNA repair pathway choice at the nuclear periphery.Nature cell biology · 2023Article
- Regulation of DNA damage response by trimeric G-proteins.iScience · 2023Article
- APOBEC3C, a nucleolar protein induced by genotoxins, is excluded from DNA damage sites.The FEBS journal · 2022Article
- CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.Cell reports · 2021Article
- Temporal dynamics of base excision/single-strand break repair protein complex assembly/disassembly are modulated by the PARP/NADCell reports · 2021Article
- Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity.Nature communications · 2021Article
- A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma.eLife · 2021Article
- Kaposi's sarcoma-associated herpesvirus processivity factor (PF-8) recruits cellular E3 ubiquitin ligase CHFR to promote PARP1 degradation and lytic replication.PLoS pathogens · 2021Article
- Understanding the in vivo Fate of Advanced Materials by Imaging.Advanced functional materials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Targeting DNA repair pathways is a powerful strategy to treat cancers. To gauge efficacy in vivo, typical response markers include late stage effects such as tumor shrinkage, progression free survival, or invasive repeat biopsies. These approaches are often difficult to answer critical questions such as how a given drug affects single cell populations as a function of dose and time, distance from microvessels or how drug concentration (pharmacokinetics) correlates with DNA damage (pharmacodynamics). Here, we established a single-cell in vivo pharmacodynamic imaging read-out based on a truncated 53BP1 double-strand break reporter to determine whether or not poly(ADP-ribose) polymerase (PARP) inhibitor treatment leads to accumulation of DNA damage. Using this reporter, we show that not all PARP inhibitor treated tumors incur an increase in DNA damage. The method provides a framework for single cell analysis of cancer therapeutics in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.